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Abstract 
Ependymomas are glial neoplasms with a wide morphological spectrum. The majority of supratentorial ependy-
momas are known to harbor ZFTA fusions, most commonly to RELA. We present an unusual case of a 9-year-old 
boy with a supratentorial ependymoma harboring a noncanonical ZFTA-MAML2 fusion. This case had unusual 
histomorphological features lacking typical findings of ependymoma and bearing resemblance to a primitive ne-
oplasm with focal, previously undescribed myogenic differentiation. We discuss the diagnostic pitfalls in this case 
and briefly review the histological features of ependymoma with noncanonical gene fusions. Our report under-
scores the importance of molecular testing in such cases to arrive at the correct diagnosis. Supratentorial epen-
dymomas with noncanonical fusions are rare, and more studies are necessary for better risk stratification and 
identification of potential treatment targets.  
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Introduction 
Ependymomas (EPN) form a diverse group of 
morphologically and molecularly heterogeneous 
glial neoplasms [5, 14]. While the classical histologi-
cal appearance of EPN is well-described, the mor-
phological spectrum is broad and may confound di-
agnosis. Unusual features encountered in ependy-
momas include chondro-osseous elements [13, 17], 
neuropil-like islands [6], melanin-containing cells 
[4], tumor giant cells [8], neuronal differentiation 
[16], granular cell features [18], et cetera. Recent 
advances in genomic and methylome profiling have 
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identified distinct molecular subgroups character-
ized by recurrent genetic or epigenetic alterations 
that may better inform diagnosis, clinical outcomes 
and risk stratification of EPN as compared to con-
ventional light microscopic diagnosis and histologi-
cal grading [5]. The majority of supratentorial (ST) 
EPNs have gene fusions involving either ZFTA (zinc 
finger translocation associated; previously known as 
C11orf95) or YAP1. These gene fusions characterize 
the two molecular subgroups of ST-EPN: ST-EPN-
ZFTA and ST-EPN-YAP1, respectively [1, 14]. Here, 
we present an unusual case of a ST-EPN with ZFTA-
MAML2 fusion demonstrating diagnostic challenges 
due to primitive morphology, suggesting an embry-
onal neoplasm and divergent differentiation, includ-
ing hitherto undescribed myogenic differentiation. 
Our case underscores the importance of molecular 
testing in such cases to arrive at the correct diagno-
sis.  
Clinical summary  
A 9-year-old boy presented with a visible, en-
larging right forehead lump for 2 months. The child 
complained of an occasional headache but was oth-
erwise well without any focal neurological deficits. 
Brain magnetic resonance imaging (MRI) revealed a 
well-demarcated, right frontal cystic tumor with a 
mural nodule, surrounding vasogenic edema and 
midline shift (Fig. 1A-C). The tumor showed a high 
choline peak and high choline:N-acetylaspartate 
(NAA) ratio. The child underwent craniotomy, re-
vealing a well-demarcated bosselated tumor with a 
clear interface between tumor and brain (Fig. 1D-E). 
Gross total resection of the tumor was achieved (Fig. 
1F), and the postoperative course was uneventful. 
He received adjuvant radiation therapy followed by 
temozolomide. The child remained well at follow up 
9 months post-resection, with no radiological evi-
dence of recurrence.
 
Figure 1. MRI findings of the tumor. A) Axial, B) coronal and C) sagittal views showing a cystic tumor with an enhancing multilobulated 
mural nodule in the right frontal lobe with mass effect. D) Intraoperative view after lifting of dural flap, prior to resection E) Dissection of 
a well-demarcated multinodular cystic tumor. F) Final intraoperative view after gross total resection of the solid tumor showing part of 
cyst lining with ventricular wall. 
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Material and methods  
The specimen was routinely processed for par-
affin embedding and staining with hematoxylin and 
eosin (H&E). Immunohistochemistry (IHC) with com-
mercially available primary antibodies, including 
GFAP, OLIG2, synaptophysin, desmin, myogenin, 
MyoD1, CAM 5.2, EMA, INI1, BRG1, LIN28A, BCOR, 
HMB45 and Ki67, was performed following locally 
validated technical protocols.  
Gene fusion detection was performed using a 
next-generation sequencing-based anchored multi-
plex polymerase chain reaction (PCR) assay (Archer® 
FusionPlex, Boulder, CO, USA) that can detect and 
identify gene fusions involving any of 101 covered 
genes, including RELA, YAP1, MAML2, NCOA1 and 
NCOA2. Briefly, total ribonucleic acid (RNA) was ex-
tracted from formalin-fixed paraffin-embedded tis-
sue sections of tumor. 150 ng of RNA was used for 
library preparation utilizing the Archer® FusionPlex 
kit, according to the manufacturer’s protocol 
(ArcherDX, Boulder, CO, USA). The prepared library 
was sequenced using an Illumina MiniSeq se-
quencer. The data obtained was analyzed by the 
Archer Data Analysis (version 6.2.3) portal. A con-
firmatory reverse transcription-PCR was designed 
flanking the breakpoint of the two genes and the 
PCR product was Sanger-sequenced. 
DNA methylation analysis was performed using 
the Illumina Infinium Human Methylation EPIC 
BeadChip Kit according to published protocols [2, 7]. 
The results of the methylation profiling and copy 
number variation analysis were obtained using an 
automated web-based deoxyribonucleic acid (DNA) 
methylation profiling program (molecularneuropa-
thology.org) [12]. The case was also integrated onto 
the t-distributed Stochastic Neighbor Embedding (t-
SNE) analysis in the German Cancer Research Center 
(DKFZ) database.  
 
 
Figure 2. Light microscopy and immunohistochemical findings of the tumor. A) Low-power appearance of the tumor consisting of nests 
of tumor cells separated by fibrous septa, imparting a desmoplastic appearance. The bulk of the tumor cells show primitive cytomorphol-
ogy with minimal cytoplasm, imparting a nondescript “small blue cell” appearance. No perivascular pseudorosettes are seen, although 
tumor cells aggregate along blood vessels. B) A minor subset of tumor cells showed prominent intracytoplasmic fine eosinophilic granules 
(arrowheads). C) Rare tumor cells showed spindled morphology, resembling skeletal muscle fibers. D) Aggregates of tumor cells with 
eccentric nuclei and mucinous cytoplasm (arrowheads). The tumor cells were positive for E) GFAP. Very focal areas showed myogenic 
differentiation, being positive for F) desmin, G) myogenin and H) MyoD1 (F-H were images taken from same area of the tumor.) 
Clicking the figure will lead you to the full virtual slide (H&E). 
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Light microscopy  
Sections showed a discrete tumor composed of 
hypercellular sheets of small, round to ovoid cells 
with hyperchromatic nuclei and indistinct cell 
boundaries, imparting a primitive appearance to the 
tumor. In other areas, the tumor cells formed nodu-
lar aggregates, short fascicles and palisades/ trabec-
ulae, separated by fibrous septa imparting a desmo-
plastic appearance (Fig. 2A). A minor subset of tu-
mor cells showed prominent intracytoplasmic fine 
eosinophilic granules, some with a more globular 
appearance (Fig. 2B). A minor component of the tu-
mor was composed of spindled cells with eosino-
philic cytoplasm reminiscent of skeletal muscle fi-
bers (Fig. 2C). Focally, aggregates of tumor cells with 
eccentric nuclei and mucinous cytoplasm were also 
identified (Fig. 2D). No other heterologous differen-
tiation was seen. There was a distinct lack of a fibril-
lary background in the tumor. While some tumor 
cells appeared to congregate around large thick-
walled vessels, no distinctive perivascular pseudoro-
settes were present. Geographic areas of necrosis 
accompanied by dystrophic calcification were pre-
sent. The mitotic count reached up to 8 per 10 high 
power fields (3 per mm2).  
The tumor cells showed patchy positivity for 
GFAP (Fig. 2E), and focal reactivity for synaptophy-
sin, CAM 5.2 and EMA (cytoplasmic; no dot/ring-like 
pattern was found). Focally, some cells expressed 
desmin (Fig. 2F) and nuclear reactivity for myogenin 
(Fig. 2G) and MyoD1 (Fig. 2H). No neurofilament-
positive axons were identified, in keeping with the 
non-infiltrative nature of this tumor. There was re-
tained expression for INI1 and BRG1. OLIG2, LIN28A, 
BCOR and HMB45 stains were negative. The Ki67 la-
beling index reached up to 40%.  
Gene fusion detection and confirmation  
The Archer FusionPlex assay detected a ZFTA 
(exon 5)- MAML2 (exon 2) fusion (Fig. 3A). This gene 
fusion was confirmed by RT-PCR with Sanger se-
quencing of the amplicon product (Fig. 3B). 
 
 
Figure 3. A) Archer FusionPlex assay detected a ZFTA (exon 5; previously known as C11orf95)-MAML2 (exon 2) fusion, which was con-
firmed by B) Sanger sequencing.  
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DNA-based methylation analysis of the tumor 
revealed a methylation class corresponding most 
closely to “Ependymoma, RELA fusion”, with a cali-
brated score of 0.65. Concurrent copy number anal-
ysis revealed 1q gain and CDKN2A/B loss (Fig. 4A). 
No chromothripsis of chromosome 11 was present. 
On the t-SNE plot, our case localized to the methyl-
ation cluster of ST-EPN-RELA, consisting of 444 cases 
including our case, out of a total of 3272 cases of ep-
endymomas of different anatomical locations and 
molecular groups, lending further diagnostic confi-
dence (Fig. 4B). 
A final diagnosis of ST-EPN with ZFTA-MAML2 
fusion was rendered after synthesizing the patho-
logical and molecular findings of this case.  
Discussion 
ZFTA, now recognized as a key player in the on-
cogenesis of ST-EPN, confers transforming capabili-
ties upon oncogenic fusion proteins by increasing 
their translocation to the nucleus and permitting ac-
cess to the transcriptional machinery [9]. Most com-
monly, ZFTA is fused to RELA [9, 14, 19]. Being pro-
miscuous, ZFTA may also rarely fuse with alternative 
partners such as MAML2, MAML3, NCOA1, NCOA2 
and CTNNA2 [14, 18, 19]. Of note, the ZFTA-MAML2 
fusion has only been identified in 18 cases of ST-EPN 
in the literature thus far, including the current case 
[14, 18, 19]. Tumors with such alternative fusion 
partners form satellite clusters around the previ-
ously known ST-EPN-RELA cluster in the t-SNE plot 
of methylation profiles and show distinct transcrip-
tional profiles [19]. While most ST-EPN-ZFTA 
demonstrate classical features of EPN such as peri-
vascular pseudorosettes and fibrillary matrix, a re-
cent paper by Zheng et al found that EPNs with ZFTA 
fusions with alternative partners tend to demon-
strate unusual histological features. These include 
sarcomatous features, areas mimicking high grade 
central nervous system (CNS) neoplasms like diffuse 
high-grade glioma, CNS embryonal tumors and 
other primitive tumors [19]. Such atypical histologi-
cal findings are in keeping with the case we present 
herein.  
Similar to the case by Tamai et al, our case also 
demonstrated granular cell features [18]. In their 
case, the granular cells showed eccentrically placed 
nuclei and cytoplasm filled with eosinophilic gran-
ules which were positive for periodic acid-Schiff 
(PAS) and alpha-1-antitrypsin stains. In addition, our 
case showed a small population of tumor cells with 
unequivocal expression for desmin, myogenin and 
myoD1, consistent with myogenic differentiation, a 
finding which has not been previously described. In-
itial diagnosis on the basis of light microscopy was 
difficult because of the atypical morphologic fea-
tures of the tumor including the conspicuous ab-
sence of a fibrillary stroma, the absence of classical 
EPN morphology, and the presence of primitive-ap-
pearing cells in a desmoplastic background. Coupled 
with the polyphenotypic immunoprofile, which in-
cluded desmin reactivity, the differential of desmo-
plastic small round cell tumor was initially enter-
tained [10]. However, the subsequent molecular 
finding of the ZFTA-MAML2 gene fusion and the ab-
sence of an EWSR1-WT1 fusion clinched the diagno-
sis of ST-EPN with ZFTA-MAML2 fusion and led to re-
vision of the histologic diagnosis. Recurrent fusions 
involving ZFTA are characteristic of EPN and fusions 
involving this gene have only been described previ-
ously in chondroid lipoma [15]. No primitive tumor 
has been described in the literature with this char-
acteristic fusion to date. While lacking in histological 
elements of classical EPN, the circumscribed, non-in-
filtrative nature of this tumor and the presence of 
the signature fusion and methylation profile were all 
in keeping with a diagnosis of ST-EPN. The novel 
finding of myogenic differentiation, likely attributa-
ble to metaplasia of the neoplastic glial component 
or the mesenchymal component of the tumor cells, 
broadens the spectrum of heterologous differentia-
tion in EPN [3]. The protean morphological manifes-
tations of EPN has the potential to obfuscate mor-
phological diagnosis, particularly when classical EPN 
features are not present. This underscores the limi-
tations of morphological evaluation alone and the 
necessity of molecular testing. 
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Figure 4. A) Copy number variation profile of the tumor, with 1q gain and CDKN2A/B losses. B) t-distributed Stochastic Neighbor Embed-
ding (t-SNE) plot containing a total of 3272 cases of EPNs for cluster analysis. Our case localized to methylation cluster of supratentorial 
EPN with RELA fusion (n= 444, including our case) (Inset, case indicated in black).  
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There has been longstanding controversy sur-
rounding the utility of histological grading of EPN. 
While ST-EPN-RELA was found to be associated with 
adverse patient outcomes in one retrospective 
study [14], this was not reproduced in another trial-
based study [11]. Interestingly, mice with EPN in-
duced by ZFTA-MAML2 fusion demonstrated a re-
duced survival compared to those with ZFTA-RELA 
fusion [19]. Out of the 18 cases of ST-EPN with ZFTA-
MAML2 fusion, follow up data was only available in 
two cases. Both cases showed anaplastic features, 
corresponded to WHO grade 3. The case reported by 
Tamai et al. showed no recurrence for 30 months 
without chemoradiotherapy, which may indicate a 
favorable prognosis [18]. Our patient remained dis-
ease free at 9 months follow up. Owing to the pau-
city of survival data, it remains to be seen if differ-
ences in survival exist in ST-EPN with alternative fu-
sions. Similarly, the utility of assignment of a WHO 
grade to molecularly defined EPN remains insuffi-
ciently characterized [5]. Additional studies are nec-
essary to better delineate the behavior of these tu-
mors, which may inform treatment decisions and 
risk stratification. 
In conclusion, we present an unusual case of 
ST-EPN with ZFTA-MAML2 fusion exhibiting primi-
tive morphology and a focal area of previously un-
described myogenic differentiation. Awareness of 
the multifaceted appearance of EPN is critical and an 
integrated clinico-pathological-molecular diagnosis 
is essential for the contemporary diagnosis of this 
entity.  
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